Summary
Olmesartan does not reduce the incidence of atrial fibrillation (AF) episodes among patients with paroxysmal AF without structural heart disease, according to findings from the Angiotensin II Antagonist in Paroxysmal Atrial Fibrillation [ANTIPAF; NCT0098137] trial.
- Cardiology Clinical Trials
- Arrhythmias
- © 2010 MD Conference Express
Tools
ARB Therapy in the Setting of Paroxysmal AF: Results from the ANTIPAF Trial
Permalink:
Table of contents
Cited By...
- No citing articles found.